Perrigo Company plc Allowance for Loan and Lease Losses, Write-offs
Perrigo Company plc (PRGO) reported Allowance for Loan and Lease Losses, Write-offs of $800.00 thousand for the 3-month period ending 2022-04-02, per its 10-Q filed 2022-05-11.
Discontinued › Notes
us-gaap:AllowanceForLoanAndLeaseLossesWriteOffs · last filed 2022-05-11
- Perrigo Company plc allowance for loan and lease losses, write-offs for the quarter ending 2022-04-02 was $800.00K, a 300.00% increase year-over-year.
- Perrigo Company plc allowance for loan and lease losses, write-offs for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- Perrigo Company plc allowance for loan and lease losses, write-offs for the quarter ending 2021-10-02 was $0.00, a 100.00% decline year-over-year.
- Perrigo Company plc allowance for loan and lease losses, write-offs for the quarter ending 2021-07-03 was $600.00K, a 33.33% decline year-over-year.
- Perrigo Company plc allowance for loan and lease losses, write-offs for fiscal 2021 was $700.00K, a 68.18% decline from fiscal 2020.
- Perrigo Company plc allowance for loan and lease losses, write-offs for fiscal 2020 was $2.20M.
| Period end | Allowance for Loan and Lease Losses, Write-offs 3 month | Allowance for Loan and Lease Losses, Write-offs 3 month as first filed | Allowance for Loan and Lease Losses, Write-offs 6 month | Allowance for Loan and Lease Losses, Write-offs 6 month as first filed | Allowance for Loan and Lease Losses, Write-offs 9 month | Allowance for Loan and Lease Losses, Write-offs 9 month as first filed | Allowance for Loan and Lease Losses, Write-offs 12 month | Allowance for Loan and Lease Losses, Write-offs 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-04-02 | $800.00K 10-Q · filed 2022-05-11 | $800.00K derived: sum of 2 quarters · filed 2022-05-11 | $800.00K derived: sum of 3 quarters · filed 2022-05-11 | $1.40M derived: sum of 4 quarters · filed 2022-05-11 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $600.00K derived: sum of 3 quarters · filed 2022-03-01 | $700.00K 10-K · filed 2022-03-01 | ||||
| 2021-10-02 | $0.00 10-Q · filed 2021-11-12 | $600.00K derived: sum of 2 quarters · filed 2021-11-12 | $700.00K 10-Q · filed 2021-11-12 | $1.50M derived: sum of 4 quarters · filed 2022-05-11 | ||||
| 2021-07-03 | $600.00K 10-Q · filed 2021-08-11 | $900.00K 10-Q · filed 2021-08-11 | $1.50M derived: sum of 3 quarters · filed 2022-05-11 | $1.90M derived: sum of 4 quarters · filed 2022-05-11 | ||||
| 2021-04-03 | $200.00K 10-Q · filed 2022-05-11 | $0.00 10-Q · filed 2021-05-12 | $900.00K derived: sum of 2 quarters · filed 2022-05-11 | $1.30M derived: sum of 3 quarters · filed 2022-05-11 | $2.20M derived: sum of 4 quarters · filed 2022-05-11 | |||
| 2020-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $1.10M derived: sum of 2 quarters · filed 2022-03-01 | $2.00M derived: sum of 3 quarters · filed 2022-03-01 | $2.20M 10-K · filed 2022-03-01 | $2.30M 10-K · filed 2021-03-01 | |||
| 2020-09-26 | $400.00K 10-Q · filed 2021-11-12 | $700.00K 10-Q · filed 2020-11-05 | $1.30M derived: sum of 2 quarters · filed 2021-11-12 | $1.50M 10-Q · filed 2021-11-12 | $1.70M 10-Q · filed 2020-11-05 | |||
| 2020-06-27 | $900.00K 10-Q · filed 2021-08-11 | $1.10M 10-Q · filed 2020-08-05 | $1.10M 10-Q · filed 2021-08-11 | $1.20M 10-Q · filed 2020-08-05 | ||||
| 2020-03-28 | $0.00 10-Q · filed 2021-05-12 | $100.00K 10-Q · filed 2020-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |